

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (previously presented) An isolated biopolymer marker peptide consisting of SEQ ID NO: 2 diagnostic for insulin resistance.

Claims 2-38. (cancelled)

Claim 39. (withdrawn) A method for diagnosing insulin resistance comprising:

- (a) obtaining a sample from a patient;
- (b) conducting mass spectrometric analysis on said sample ~~in a manner effective to maximize elucidation of discernible to~~ elucidate peptide fragments contained therein; and
- (c) comparing mass spectrum profiles of an isolated biopolymer marker peptide consisting of SEQ ID NO: 2 to mass spectrum profiles of peptides elucidated from said sample; wherein recognition of a mass spectrum profile in the sample displaying the characteristic

profile of the mass spectrum profile for the isolated biopolymer marker peptide consisting of SEQ ID NO:2 is diagnostic for insulin resistance.

Claim 40. (withdrawn) The method of claim 39, wherein said sample is an unfractionated body fluid or a tissue sample.

Claim 41. (withdrawn) The method of claim 39, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 42. (currently amended) The method of claim 39, wherein said mass spectrometric analysis is selected from the group consisting of Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS), ~~Maldi-Qq-TOF~~ Matrix-Assisted Laser Desorption/ Quadrupole quadrupole Time-Of-Flight (MALDI-TOF) mass spectrometry, [[MS/MS]] multiple sequential Mass Spectrometry (MS/MS), multiple sequential Time-Of-Flight/Time-Of-Flight (TOF-TOF) mass spectrometry ~~TOF-TOF~~, Electrospray Ionization/ Ionization Time-Of-Flight (ESI-Q-TOF) mass spectrometry ~~ESI-Q-TOF~~ and ION-TRAP mass spectrometry.

Claim 43. (withdrawn) The method of claim 39, wherein said

patient is a human.

Claim 44. (withdrawn) An insulin resistance diagnostic kit comprising: (a) an isolated biopolymer marker peptide selected from the group consisting of SEQ ID NO: 2 and (b) an antibody that binds to said isolated biopolymer marker peptide in a sample from a patient.

Claim 45. (withdrawn) The insulin resistance diagnostic kit of claim 44, wherein said antibody is immobilized on a solid support.

Claim 46. (withdrawn) The insulin resistance diagnostic kit of claim 44, wherein said antibody is labeled.